SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Lismore Damian T. (Last) (First) (Middle) C/O NEXVET BIOPHARMA PLC NIBRT, FOSTERS AVENUE, MOUT MERRION (Street) BLACKROCK L2 00000 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/04/2015	3. Issuer Name and Ticker or Trading Symbol Nexvet Biopharma plc [ NVET ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	7,080	I	By Spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preference Shares	(1)	(1)	Ordinary Shares	13,724	(1)	I	Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C>(2)
Warrant to Purchase Shares	06/02/2014	06/02/2019	Ordinary Shares	5,147	$8.625	I	Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C>(2)
Option to Purchase Shares	07/01/2015(3)	07/01/2019	Ordinary Shares	18,000	$0.125	D
Option to Purchase Shares	11/05/2014(4)	11/05/2023	Ordinary Shares	14,159	$0.125	I	By spouse

Explanation of Responses:

1. The Series B Preference Shares will convert immediately upon the effectiveness of an initial public offering of Issuer's ordinary shares on a one-for-one basis and have no Expiration Date.

2. The reporting person and his spouse have shared voting and dispositive power with respect to these reported securities.

3. 4,000 options to purchase shares shall vest and become exercisable on each of 7/1/15, 7/1/16 and 7/1/17. The remaining 6,000 options to purchase shares will vest and become exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors which completion must occur on or before 7/1/19.

4. 7,080 options to purchase shares will vest and become exercisable on 11/5/15, and the remaining 7,079 options to purchase shares will vest and become exercisable on 11/5/16.

	/s/ Damian Lismore	02/04/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.